Neurocrine Biosciences Inc (NBIX) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Neurocrine Biosciences Inc, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track NBIX live on Mooboard →

Later15

  • Feb 2027
    Neurocrine Biosciences Inc(NBIX)Phase 2/3 readout
    NBI-1065890 · Phase 2 · Tardive Dyskinesia
    NCT07365462: Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia. Primary completion 2027-02 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 2027
    Neurocrine Biosciences Inc(NBIX)Phase 2/3 readout
    NBI-1065845 · Phase 3 · Major Depressive Disorder
    NCT06911112: NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD). Primary completion 2027-07 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 2027
    Neurocrine Biosciences Inc(NBIX)Phase 2/3 readout
    NBI-1065845 · Phase 3 · Major Depressive Disorder
    NCT06786624: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD). Primary completion 2027-07 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 2027
    Neurocrine Biosciences Inc(NBIX)Phase 2/3 readout
    NBI-1065845 · Phase 3 · Major Depressive Disorder
    NCT06963021: NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD). Primary completion 2027-07 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Aug 2027
    Neurocrine Biosciences Inc(NBIX)Phase 2/3 readout
    NBI-1117570 · Phase 2 · Schizophrenia
    NCT07288333: Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia. Primary completion 2027-08 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 2027
    Neurocrine Biosciences Inc(NBIX)Phase 2/3 readout
    NBI-1117568 · Phase 3 · Schizophrenia
    NCT06963034: NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia. Primary completion 2027-10 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 2027
    Neurocrine Biosciences Inc(NBIX)Phase 2/3 readout
    NBI-1117568 · Phase 3 · Schizophrenia
    NCT07105098: NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia. Primary completion 2027-11 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 2028
    Neurocrine Biosciences Inc(NBIX)Phase 2/3 readout
    NBI-1117568 · Phase 2 · Bipolar I Disorder; Mania
    NCT07288320: An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania. Primary completion 2028-02 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 2028
    Neurocrine Biosciences Inc(NBIX)Phase 2/3 readout
    Crinecerfont · Phase 2 · Congenital Adrenal Hyperplasia
    NCT07536269: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old. Primary completion 2028-03 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 2028
    Neurocrine Biosciences Inc(NBIX)Phase 2/3 readout
    Valbenazine · Phase 3 · Chorea, Huntington
    NCT06312189: Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada. Primary completion 2028-04 (estimated); status ENROLLING_BY_INVITATION.
    ClinicalTrials.gov ↗
  • Jul 2028
    Neurocrine Biosciences Inc(NBIX)Phase 2/3 readout
    NBI-1065845 · Phase 3 · Major Depressive Disorder
    NCT07196501: A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD). Primary completion 2028-07 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • May 2029
    Neurocrine Biosciences Inc(NBIX)Phase 2/3 readout
    NBI-1065845 · Phase 3 · Major Depressive Disorder
    NCT06966401: Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD). Primary completion 2029-05 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 2029
    Neurocrine Biosciences Inc(NBIX)Phase 2/3 readout
    NBI-1117568 · Phase 3 · Schizophrenia
    NCT07227818: Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia. Primary completion 2029-07 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 6, 2029
    Neurocrine Biosciences Inc(NBIX)Phase 2/3 readout
    Crinecerfont · Phase 2 · Congenital Adrenal Hyperplasia
    NCT07187375: Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old. Primary completion 2029-09-06 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 2031
    Neurocrine Biosciences Inc(NBIX)Phase 2/3 readout
    NBI-1117568 · Phase 3 · Schizophrenia
    NCT07114874: NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia. Primary completion 2031-12 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗

How Neurocrine Biosciences Inc has moved — past-year price reactions

How binary is NBIX? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.1%
typical day (1Y)
2
±10% days
33.3%
annualized vol
250
trading days
Largest single-day moves
  • -10.4%2026-02-12no matched headline
  • -10.1%2026-07-31no matched headline
  • +8.9%2026-05-06no matched headline
  • +7.4%2025-11-05no matched headline
  • +6.6%2026-06-03no matched headline
  • -6.4%2025-10-29no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Neurocrine Biosciences Inc — active clinical pipeline

Neurocrine Biosciences Inc's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

6 assets9 programsPh1 0Ph2 4Ph3 4· 1 post-marketing (Ph4)
AreasNeuroscienceOther
CrinecerfontOther · CRHR1
Phase 2
Congenital Adrenal Hyperplasia (2)
Phase 3
Congenital Adrenal Hyperplasia (2)
NBI-1117568Neuroscience
Phase 2
Bipolar I Disorder
Phase 3
Schizophrenia (4)
NBI-1065845Neuroscience
Phase 3
Major Depressive Disorder (5)
ValbenazineNeuroscience · SLC18A2
Phase 3
Chorea, Huntington
NBI-1065890Other
Phase 2
Tardive Dyskinesia
NBI-1117570Neuroscience
Phase 2
Schizophrenia

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

See the full biopharma catalyst calendar across all covered companies.